Meta-analysisindependent cross-checkabstract only checked I-ODD-15 standard review
Semaglutide and NAION: pooled analysis 2
Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis.
Overview
Dhivagaran T et al.. Neurology 2026 · PMID 42060879 · DOI 10.1212/WNL.0000000000214864
Risk about 2.5 times higher, but absolute risk about 1 per 1,000 users.
Does the study support the specific claim? Yes · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
GLP-1 RA use and NAION risk
- How was the study done?
Systematic review and Bayesian meta-analysis (ROBINS-I, GRADE)
- How many people, animals or samples were studied?
5 studies; 1,593,554 patients; GLP-1 RA users vs non-users
- What was actually found?
RR 2.52.
- How large was the observed effect?
RR 2.52 (1.56-4.72)
- What do the results mean in everyday life?
Possible rare eye risk.
- What are the study's limitations?
Observational inputs; Heterogeneous incidence
- What does it say about Elawady's specific claim?
Supports C-ODD-10.
- Do the results apply to Germany and Europe?
Multinational.
- What can explicitly not be concluded from this study?
Causation definitively.
Scientific in-depth review
1. Full reference
- Authors
- Dhivagaran T et al.
- Journal
- Neurology
- Year
- 2026
- Identifier
- PMID 42060879 DOI 10.1212/WNL.0000000000214864
- Verification
- verified – PubMed efetch 2026-10-25 (this agent)
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract
2. Research question
GLP-1 RA use and NAION risk
3. Study design and population
- Study design
- Meta-analysis – Systematic review and Bayesian meta-analysis (ROBINS-I, GRADE)
- Population
GLP-1 RA users vs non-users
- Country
International
- Period
To April 2025
- Sample size
5 studies; 1,593,554 patients
- Inclusion and exclusion criteria
As described in the abstract; details not available in abstract.
4. Methods and endpoints
- Exposure / intervention
Semaglutide/GLP-1 RAs
- Comparator
Non-GLP-1 RA
- Endpoints
NAION
- Statistical methods
Bayesian random effects
5. Actual results
- Results
Semaglutide RR 2.52 (95% CrI 1.56-4.72); diabetes RR 2.41; incidence 85 per 100,000 GLP-1 RA users; 118 per 100,000 semaglutide users.
- Absolute risks
About 118 per 100,000 semaglutide users.
- Authors' conclusion
Low-to-moderate certainty evidence that semaglutide increases NAION risk, particularly in diabetes.
6. Strengths
- Risk-of-bias assessment
- Sensitivity analyses
7. Weaknesses
- Observational inputs
- Heterogeneous incidence
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
Observational inputs.
9. Assessment of the statistical interpretation
Relative increase with low absolute incidence.
10. Relevance to the specific claim
Supports C-ODD-10.
11. Independent contrary findings
12. Transferability to Germany and Europe
Multinational.
13. Overall methodological judgement
Supports a possible rare risk.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | some concerns |
| Precision of results | moderate |
| Directness | direct |
| Reproducibility | partly replicated |
| Consistency with the overall evidence | inconsistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
None beyond those stated.